Indian drugmakers prepare lower-cost versions of Ozempic-like drugs as competition intensifies

Summary

Indian pharmaceutical companies are gearing up to introduce more affordable versions of semaglutide-based therapies used for diabetes and weight management, as competition builds and demand rises. Pricing pressure is expected to increase, improving access over time.

NEW DELHI, March 23, 2026 — Indian drugmakers are preparing to expand the availability of lower-cost alternatives to semaglutide-based therapies, widely known through brands such as Ozempic and Wegovy, as demand for diabetes and weight-management treatments grows rapidly.

Several domestic pharmaceutical companies have indicated plans to introduce their own versions of the drug, subject to regulatory approvals and intellectual property considerations. Industry analysts expect increased competition to gradually bring down prices in the local market.

Semaglutide, a GLP-1 receptor agonist, has seen strong global demand due to its effectiveness in managing blood sugar levels and aiding weight loss. However, high prices have limited access in many emerging markets, including India.

Companies are exploring different delivery formats, including injectable pens and oral formulations, though availability and timelines will depend on regulatory clearance and manufacturing scale-up.

Health experts caution that such therapies should be used strictly under medical supervision, as they are prescription medicines with potential side effects.

India has one of the world’s largest populations of diabetes patients, and broader access to newer therapies could play a role in long-term disease management, analysts said.

Why this matters

• Affordability: Increased competition could gradually reduce treatment costs for patients
• Healthcare access: Wider availability may improve diabetes management outcomes
• Market opportunity: Strong demand is driving investment and innovation among Indian drugmakers

FAQs

Q1. Are generic versions of semaglutide widely available in India?

Availability depends on regulatory approvals and patent considerations. Companies are preparing launches, but rollout timelines may vary.

Q2. Will prices drop significantly?

Greater competition typically leads to price reductions over time, though the extent is uncertain.

Q3. Can these medicines be used without a prescription?

No. Semaglutide-based therapies are prescription drugs and must be used under medical supervision.